<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
COR Therapeutics, Inc.
-----------------------------------------
(Name of Issuer)
Common Stock
-----------------------------------------
(Title of Class of Securities)
217753102
-----------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
1. Name of Reporting Person
S.S. or I.R.S. or I.R.S. Identification No. of Above Person
UBS Asset Management (New York) Inc.
Tax ID: 13-2725861
2. Check the Appropriate Box if a Member of a Group
a.[ ]
b.[ ]
SEC Use Only
4. Citizenship or Place of Organization
New York
5. Sole Voting Power:
- 0 -
Number of 6. Shared Voting Power:
Shares
Beneficially - 0 -
Owned by
Each 7. Sole Dispositive Power:
Reporting
Person 1,050,500
With
8. Shared Dispositive Power:
- 0 -
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,050,500
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
11. Percent of Class Represented by Amount in Row (9)
4.56%
12. Type of Reporting Person
IA
-2-
<PAGE> 3
CUSIP Number: 217753102
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
UBS (Lux) Equity Invest-Biotech, a Subfund of UBS (Lux) Equity Invest
2. Check the Appropriate Box if a Member of a Group
a.[ ]
b.[ ]
3. SEC Use Only
4. Citizenship or Place of Organization
Luxembourg
5. Sole Voting Power:
1,050,500
Number of 6. Shared Voting Power:
Shares
Beneficially - 0 -
Owned by
Each 7. Sole Dispositive Power:
Reporting
Person - 0 -
With
8. Shared Dispositive Power:
- 0 -
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,050,500
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
11. Percent of Class Represented by Amount in Row (9)
4.56%
12. Type of Reporting Person
OO
-3-
<PAGE> 4
Item 1(a) name of Issuer: Cor Therapeutics, Inc. (the "Company")
(b) Address of Issuer's Principal Executive Offices:
Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons
Filing:
UBS Asset Management (New York) Inc.
1345 Avenue of the Americas
New York, New York 10105
UBS (Lux) Equity Invest - Biotech,
a subfund of UBS (Lux) Equity Invest
c/o INTRAG International
Equity Invest (Company for Fund Management) S.A.
Luxembourg
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 217753102
Item 3. This statement is filed pursuant to Rule 13d-1(b)(1) and 13d-1(b)(2).
UBS Asset Management (New York) Inc. is an investment adviser
registered under Section 203 of the Investment Advisers Act of 1940.
UBS (Lux) Equity Invest - Biotech, a subfund of UBS (Lux) Equity
Invest is an investment fund organized under Luxembourg law.
-4-
<PAGE> 5
Item 4. Ownership.
UBS Asset Management (New York) Inc. and UBS (Lux) Equity Invest-Biotech,
a Subfund of UBS (Lux) Equity Invest beneficially own 1,050,500 shares of the
Company's Common Stock (representing approximately 4.56% of the outstanding
shares of such Common Stock). UBS Asset Management (New York) Inc. possesses
the power to dispose of and direct the disposition of all 1,050,500 shares. UBS
(Lux) Equity Invest-Biotech, a Subfund of UBS (Lux) Equity Invest possesses the
power to vote or direct the vote of all 1,050,500 Shares. The holdings listed
are as of January 31, 1998.
Item 5. Ownership of Five Percent or Less of a Class.
See Item 4.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported by the Parent Holding Company.
Not Applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of the Group.
Not Applicable.
Item 10. By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course
of business and were not acquired for the purpose and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purpose or effect.
-5-
<PAGE> 6
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
UBS Asset Management (New York) Inc.
By: /s/ Joseph Scavo February 13, 1998
----------------------------- -----------------
Title: Director of Compliance Date
INTRAG International Equity Invest (Company for Fund Management) S.A.
By: /s/ Gilbert Schintgen February 13, 1998
----------------------------- -----------------
Title: Director Date
By: /s/ Manuel Hauser February 13, 1998
----------------------------- -----------------
Title: Director Date
-6-
